ERBB2 and breast cancer: Finally, the DESTINY-Breast04 trial evaluated the use of T-Dxd versus physician’s choice chemotherapy in 577 patients with low HER2+ metastatic BC who had received prior chemotherapy in the metastatic setting or developed a recurrence within 6 months of completing adjuvant chemotherapy.